Merck Gets EC Approval For Keytruda Regimens in Head, Neck Cancer
November 20 2019 - 7:36AM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Wednesday said the European Commission
approved two new regimens of its cancer drug Keytruda as first-line
treatment for metastatic or unresectable recurrent head and neck
squamous cell carcinoma.
The Kenilworth, N.J., drug maker said the approval includes
Keytruda as monotherapy or in combination with platinum and
5-fluorouracil chemotherapy, for the first-line treatment of
patients whose tumors express PD-L1.
Merck said the approval is based on a phase 3 study in which
Keytruda, compared with standard treatment, showed a significant
improvement in overall survival as monotherapy and in combination
with chemotherapy in such patients.
The company said Keytruda is the first anti-PD-1 treatment
option approved in Europe in the first-line setting for metastatic
or unresectable recurrent head and neck cancer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 20, 2019 07:21 ET (12:21 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024